Zai gains China rights to Paratek's omadacycline

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) granted Zai Lab Ltd. (Shanghai, China) exclusive rights in Greater China to antibiotic candidate omadacycline (formerly PTK 0796). Paratek received $7.5 million up front, and is eligible for milestones and royalties.

Paratek declined to disclose additional financial terms, and Zai did not respond to inquiries...